

Croda International Plc: Proposed acquisition of Iberchem and c.£600m placing

November 2020



Cautionary statement 1 of 2

THIS PRESENTATION, ITS CONTENTS AND ANY INFORMATION PROVIDED AT THIS PRESENTATION ARE STRICTLY CONFIDENTIAL AND ARE FOR DISCUSSION PURPOSES ONLY AND MUST NOT BE RELIED UPON FOR ANY PURPOSE. THIS PRESENTATION IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (EXCEPT TO QIBS), CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA, OR TO ANY RESIDENT THEREOF, OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE UNLAWFUL OR TO ANY OTHER PERSON. THIS PRESENTATION IS NOT AN OFFER OR INVITATION TO BUY OR SELL SECURITIES.

This document has been prepared by Croda International plc (referred to herein as "Croda" or the "Company") solely for informational purposes. For the purposes of this notice, the presentation shall mean and include the slides that precede this notice, this document, the oral presentation of the slides by the Company or any person on behalf of the Company, any audio-visual materials, its contents or any part of it, any question-and-answer session that follows the oral presentation, hard copies of this document and any materials distributed at, or in connection with the presentation (collectively, the "Presentation"). By attending the meeting at which the Presentation is made, or by reading the Presentation, you will be deemed to have (i) agreed to all of the following restrictions and made the following undertakings and (ii) acknowledged that you understand the legal and regulatory sanctions attached to the misuse, disclosure or improper circulation of the Presentation. You must keep this Presentation confidential. This Presentation has been prepared and issued by and is the sole responsibility of the Company and is being furnished to each recipient solely for its own information and in connection with the preliminary discussions in relation to the Company.

This Presentation is not a prospectus for the purposes of the Prospectus Regulation Rules of the Financial Conduct Authority (the "FCA") or otherwise and this Presentation has not been approved by the FCA or any other regulatory authority. Investors should not subscribe for or purchase any securities referred to in this Presentation and is not intended to provide, and must not be taken as, the basis of any decision and should not be considered as a recommendation to acquire any securities of the Company. The Company has not decided whether or not to proceed with any offering of securities or proposed application for admission of its securities to trading on a regulated market in the United Kingdom. The recipient must make its own independent assessment and such investigations as it deems necessary.

The information contained in this Presentation is strictly private and confidential and may not be reproduced, redistributed or disclosed in any way in whole or in part to any other person without the prior written consent of the Company. Save as set out below, the Presentation has been prepared on the basis of information held by the Company and also from publicly available information. This Presentation does not purport to contain all the information that may be required by the recipient to make an evaluation of the Company. The Company prepared this Presentation on the basis of information which it has and from sources believed to be reliable. To the extent available, the industry, market and competitive position data contained in this Presentation come from official or third-party sources. Third-party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications, studies and surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the industry, market and competitive position data contained in this Presentation come from the Company's own internal research and estimates based on the knowledge and experience of the Company's management in the market in which the Company operates. While the Company believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are by reference to the time the Presentation was prepared and are subject to change without notice. Accordingly, undue reliance should not be placed on any of the industry, market or competitive position data contained in this Presentation. Neither the Company, the Joint Global Co-ordinators (as defined below) nor any of such person's respective directors, officers, employees, agents, affiliates or advisers is under any obligation to update or keep current the information contained in the Presentation to which it relates or to provide the recipient of with access to any additional information that may arise in connection with it and any opinions expressed in this Presentation are subject to change without notice. Nothing contained in this Presentation is or should be relied upon as a promise or representation as to the future.

None of HSBC Bank plc ("HSBC") and Morgan Stanley & Co. International plc ("Morgan Stanley") and together with HSBC, the "Joint Global Co-ordinators"), any of their respective directors, officers, employees, agents, affiliates and consultants ("Associates") or advisers have independently verified the information in this document and such information does not constitute a recommendation from the Joint Global Co-ordinators to you. None of the Joint Global Co-ordinators or the Associates accepts any responsibility, obligation or liability whatsoever for, or makes any representation or warranty, express or implied, as to, and no reliance should be placed on, the fairness, truth, fullness, accuracy, completeness or correctness of, the information in this Presentation or whether any information has been omitted from the Presentation or as to any other information relating to the Company, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this Presentation, its contents or otherwise arising in connection therewith. Each of the Joint Global Co-ordinators and their respective Associates disclaim, to the maximum extent permitted by applicable law and regulation, all and any indirect or direct responsibility and liability whether express or implied, arising in tort, contract or otherwise, which they might otherwise have in respect of (i) the Presentation or any information contained therein and (ii) any errors, omissions or misstatements contained in the Presentation. The Presentation has not been independently verified. None of the Joint Global Co-ordinators or their respective Associates shall have any liability whatsoever (in negligence or otherwise) for any direct, indirect or consequential loss, damages, costs or prejudices arising from the use of this Presentation or otherwise arising in connection with this Presentation. No duty of care is owed or will be deemed to be owed to you or any other person by the Joint Global Co-ordinators or their Associates in respect of the Presentation.

Cautionary statement 2 of 2

No representation or warranty, express or implied, is given by or on behalf of the Company or any of its parent or subsidiary undertakings or any of such person's respective directors, officers, employees, agents, affiliates or advisers as to, and no reliance should be placed on, the fairness, truth, fullness, accuracy, completeness or correctness of the information or opinions contained in this Presentation or otherwise made available nor as to the reasonableness of any information contained herein or therein and no responsibility or liability (including in respect of direct, indirect or consequential loss or damage) is assumed by any such persons for such information or opinions or for any errors or omissions. The recipient acknowledges that neither it nor the Company intends that the Company act or be responsible as a fiduciary to the recipient of this document or presentation, its management, stockholders, creditors or any other person. Each of the recipient and the Company by accepting and providing this Presentation respectively expressly disclaims any fiduciary relationship and agrees that the recipient is responsible for making its own independent judgments with respect to any transaction and any other matters regarding this Presentation.

The recipient should conduct its own independent investigation and assessment as to the validity of the information contained in this Presentation, and the economic, financial, regulatory, legal, taxation, stamp duty and accounting implications of that information. The recipient confirms that it is not relying on any recommendation or statement of the Company, the Joint Global Co-ordinators or any of their respective Associates. The recipient is strongly advised to consult its own independent advisors on any economic, financial, regulatory, legal, taxation, stamp duty and accounting issues relating to the information contained in this Presentation.

This Presentation may contain certain forward-looking statements, forecasts, estimates, projections and opinions ("Forward Statements"), which are based on current assumptions and estimates by the management of Croda. These Forward Statements include all matters that are not historical facts. These Forward Statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "plans", "may", "will" or "should" or, in each case, their negative or other variations or comparable terminology. By their nature, Forward Statements involve known and unknown risks, uncertainties, assumptions and other factors because they relate to events and depend on circumstances that will occur in the future whether or not outside the control of the Company. Past performance cannot be relied upon as a guide to future performance and should not be taken as a representation that trends or activities underlying past performance will continue in the future. No representation or guarantee is made or will be made that any Forward Statements will be achieved or will prove to be correct. Actual future results and operations could vary materially from the Forward Statements. Similarly, no representation or guarantee is given that the assumptions disclosed in this Presentation upon which Forward Statements may be based are reasonable. The recipient acknowledges that circumstances may change and the contents of this Presentation may become outdated as a result. Each of the Company, the Joint Global Co-ordinators, and their respective Associates undertakes no obligation to update these Forward Statements, which speak only as at the date of this Presentation, and have not been audited or otherwise independently verified, and will not publicly release any revisions that may be made to these Forward Statements, which may result from events or circumstances arising after the date of this Presentation. No statement in this Presentation is intended to be a profit forecast. As a result, you are cautioned not to place any undue reliance on such forward-looking statements. In addition, even if the results of operations, financial condition and liquidity of the Company, and the development of the industry in which the Company operates, are consistent with the Forward Statements set out in this Presentation, those results or developments may not be indicative of results or developments in subsequent periods.

HSBC is authorised by the Prudential Regulation Authority (the "PRA") and regulated in the United Kingdom by the FCA and the PRA. HSBC is registered with registered number 14259 and has its registered office at 8 Canada Square, London E14 5HQ, United Kingdom. Morgan Stanley is authorised by the PRA and regulated in the United Kingdom by the FCA and the PRA. Morgan Stanley is registered with registered number 2068222 and has its registered office at 25 Cabot Square, Canary Wharf, London E14 4QA, United Kingdom. Each of the Joint Global Co-ordinators is acting exclusively for the Company and no one else in connection with this Presentation or any future transaction in connection with it. Each of the Joint Global Co-ordinators will not regard any other person (whether or not a recipient of this Presentation) as a client and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients nor for the giving of advice in relation to any transaction, matter or arrangement of securities of the Company referred to in this Presentation.

This Presentation is not an offer to sell or a solicitation of an offer to buy any securities and is not for publication or distribution in the United States except to QIBs (as defined below). The securities have not been, and will not be, registered under the U.S. Securities Act of 1933 (the "Securities Act") and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and in accordance with any applicable securities law of any state or other jurisdiction of the United States. The Company does not intend to register any portion of the offering in the United States or to conduct a public offering of any securities in the United States. This Presentation may not be viewed by persons within the United States (within the meaning of Regulation S under the Securities Act) other than "qualified institutional buyers" ("QIBs") (as defined in Rule 144A under the Securities Act) and in accordance with any applicable securities law of any state or other jurisdiction of the United States.

This Presentation is only addressed to and directed at persons in member states of the European Economic Area ("EEA"), other than the United Kingdom who are qualified investors within the meaning of Article 2(e) of the Prospectus Regulation (Regulation EU) 2017/1129), as amended ("Qualified Investors"). In addition, in the United Kingdom, this Presentation is addressed to and directed only at, Qualified Investors who (i) are persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), (ii) are persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order, or (iii) are other persons to whom this Presentation may otherwise lawfully be communicated (all such persons referred to in (i), (ii) and (iii) together being referred to as "Relevant Persons"). The Presentation must not be acted or relied on (i) in the United Kingdom, by persons who are not Relevant Persons and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment activity to which the Presentation relates is available only (i) in the United Kingdom, to Relevant Persons and (ii) in any member state of the EEA, to Qualified Investors, and may be engaged in only with such persons. This Presentation does not constitute an offer or invitation for the sale or purchase of securities or any businesses or assets described in it, nor does it purport to give legal, tax or financial advice. Nothing in the Presentation constitutes investment advice and any recommendations that may be contained therein have not been based upon a consideration of the investment objectives, financial situation or particular needs of any specific recipient. If you have received this Presentation and you are not a Relevant Person or a Qualified Investor you must return it immediately to the Company and not copy, reproduce or otherwise disclose it (in whole or in part).

Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this Presentation (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser's province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser's province or territory for particulars of these rights or consult with a legal advisor.

Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts ("NI 33-105"), the Joint Global Co-ordinators are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.

The Presentation does not constitute or form part of, and should not be construed as, an offer to sell or issue, or the solicitation of an offer to purchase, subscribe to or acquire, securities of the Company, or an inducement to enter into investment activity in any country, including the United States, Canada, Australia, Japan, South Africa, or in any other jurisdiction in which such offer, solicitation, inducement or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of such jurisdiction. No part of this Presentation, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever.

The Presentation is not for publication, release or distribution in any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction nor should it be taken, transmitted or distributed, directly or indirectly into such jurisdiction. Any failure to comply with the foregoing restrictions may constitute a violation of United States or other national securities laws. You are required to inform yourself of, and comply with, all such restrictions and prohibitions and none of the Company, the Joint Global Co-ordinators, their respective Associates nor any other person accepts liability to any person in relation thereto.

Agenda

- Transaction summary and financing
- About Iberchem
- Combination benefits

Transaction summary and financing

Strengthening Personal Care and Home Care with targeted F&F acquisition

Strong strategic alignment with Croda

Our purpose

Smart Science to Improve Lives™

- Fragrances have proven impact on consumers' well being
- Key ingredient in majority of beauty care products

Sector strategies

Personal Care
Strengthen
to grow


Life Sciences
Expand
to grow

Performance Technologies
Refine to grow

- Similar customer profile to Personal Care
- Crucial to the consumer experience, brand selection and loyalty
- Sustainability a potential differentiator in the market
- Aligned with “Strengthen to grow” strategy for Croda Personal Care
- Broadens Croda footprint in Consumer Care

High growth segment, particularly in emerging markets

- Global fragrance market expected to reach \$58.8bn in 2024⁽¹⁾
- 5.6% global CAGR 2020-2024⁽¹⁾
- Driven by demand in Latin America, Asia-Pacific, Middle East and Africa



Source: Euromonitor International, 2020-2024 CAGR, 2019 fixed US\$ ex. rate, current / nominal terms; Quarterly update August 2020 © 2020

Acquisition of Iberchem, a global F&F specialist

Compelling strategic rationale	
1.	Excellent financial track record
2.	Access to high growth adjacency with significant emerging markets exposure
3.	Creates a one stop shop for Consumer Care customers
4.	Proven, agile and responsive customer-centric model
5.	Dynamic, customer-driven R&D focus

Strong financial rationale	
1.	EPS accretive from year 1 and strongly accretive thereafter
2.	Significant medium and long-term revenue synergies
3.	Capital-light; strong cash conversion
4.	Acquisition ROIC to exceed Croda cost of capital within 5 years

Transaction summary and financing

Transaction summary

- €820m total consideration (c.£736m) on a debt-free, cash-free basis; 20.5x EV/EBITDA⁽¹⁾
- Funded via:
 - Group's existing debt facilities
 - Placing of new ordinary shares to institutional investors
 - Expected net proceeds of c.£600m
 - Conducted through accelerated bookbuild
 - Represents c.8% of Croda's issued share capital
- Structure of financing preserves Croda's financial flexibility with net debt forecast c.2x EBITDA⁽²⁾ post completion at end 2020, expected to de-lever to c.1.6x by end of 2021
- Croda trading to October 2020 in line with expectations; outlook unchanged

Simple completion process; expected by end of 2020

- Iberchem will operate as an independent entity
- Extensive support from Croda and integration with Croda's sales teams
- Will be reported as part of new Consumer Care sector from 2021
- Will continue to be led by existing, highly experienced management team⁽³⁾



About Iberchem

Iberchem: a global fragrance-led company with distinctive positioning

€187m
revenues in 2020F

+14%
growth
(CAGR 2016-20F)

€40m
EBITDA in 2020F



21%
EBITDA margin

Selling into **~120** countries⁽¹⁾

Headquartered in **Murcia, Spain**



850 FTEs⁽³⁾



14
Manufacturing facilities



36,500
Fragrance references

18,000
Flavour references

10
Creative and R&D centres



25%
of total Iberchem sales to China

83%
of total Iberchem sales to emerging markets

3,600 customers⁽⁴⁾

Source: company information, financials as per management accounts (unaudited)

⁽¹⁾ Based on countries where Iberchem's products are sold
⁽²⁾ FY 2019A; rounded number

⁽³⁾ As at August 2020; rounded number

⁽⁴⁾ Active customers (with accounting sales during the year) for 2019A; rounded to the nearest 100

Focused on fragrances for Personal Care and Home Care



80% fragrances


20% flavours

36,500 fragrance references

18,000 flavour references

50% Personal Care

- Perfumes
- Hair care
- Bath and shower
- Facial care



50% Home Care

- Fabric care
- Surface cleaner
- Air care
- Dishwashing




80% food and drink

20% oral care, pharmaceutical and speciality

Over 4,000 fragrance and flavour references added each year

Highly compatible business model aligned to “the Croda way”


Iberchem business model



Iberchem business model strengths	Croda key strengths
Strong growth through favourable macro-trends	✓
Focus on Personal Care and Home Care markets	✓
Leader in its selected, high-growth niches	✓
Formulation-led approach	✓
Targeting independent mid-size customers	✓
Agile, entrepreneurial culture	✓
Capital-light with low carbon footprint	✓


1. Excellent financial track record

Consistent organic growth across the cycle





- Revenue €174m (c.£153m) in 2019 and €187m (c.£166m) forecast in 2020
- Consistent growth despite recognised headwinds
- Driven by:
 - Emerging markets positioning
 - Focus on fragrances for Consumer Care applications
 - Portfolio breadth and agile business model

Strong profit growth and attractive cash profile



- EBITDA €34m (c.£30m) in 2019 and €40m (c.£36m) forecast in 2020
- Consistently attractive margins despite cost-effective offerings
 - Strong margin in 2020 despite COVID-19
- Capital-light model
 - Good cash conversion – over 80% EBITDA in 2019 and 2020F

2. Global platform with significant exposure to high growth markets



25%
of total Iberchem sales to China

83%
of total Iberchem sales to Asia, Africa, Middle East, Latin America

● Denotes local presence
● Denotes indirect presence through sale of products
🤝 Commercial office
🧪 Creative centre / R&D
🏭 Production / Warehouse

⁽¹⁾ 2019A. Source: company information, financials as per management accounts (unaudited)

3. Long-standing customer-centric model

- Strong customer intimacy⁽¹⁾
- Focused on customer niches not targeted by larger competitors
- “Fast-to-customer” model well suited to mid-size customers
- Tailor-made products
- Growth strategy targeting
 - “Own brands”
 - Larger regional and independent customers


Diversified and loyal⁽¹⁾ customer-base

Top 10 customers = **20%** revenue⁽²⁾

3,600
Customers⁽³⁾

+1,000
customers in 3 years

Number of active customers




4. Strong, customer-driven R&D focus


Formulation-led approach

- Well established culture of innovation
- 10 R&D centres and 240 R&D technicians⁽¹⁾
- 2019: invested in state-of-the-art applications laboratory
- 22 Perfumers, 9 Flavourists
- Allows rapid commercialisation of value for money fragrances and flavours and supports customer intimacy
- 36,500 fragrance and 18,000 flavour references
- 280 new fragrance and 70 flavour references created each month⁽²⁾
- Investment in latest technological solutions for creation and delivery of fragrance and flavour solutions

Commercial R&D process



State of the art and recent R&D laboratories



Combination benefits

Strong financial fundamentals and significant revenue synergies

Strong financial fundamentals

	Organic revenue ⁽¹⁾ growth	EBITDA ⁽²⁾ margin	Cash conversion ⁽³⁾	Net working capital as % sales	Capex as % sales
2019A	20.0%	19.7%	85.3%	25.5%	2.9%
2020F	7.4%	21.2%	84.5%	28.8%	3.3%

Targeting €25m annual revenue synergies by year 3 and €48m by year 5



Croda and Iberchem – creating a full service formulation and fragrance offer


EXAMPLE FORMULA	
Croda “Clearly Conditioning” Shampoo	
Ingredients	% w/w
Deionised Water	67.40
Standard cleansing agent	20.00
Crodateric CAB 30	5.00
Versathix	3.00
Crovol A70	1.50
Lusterplex	1.00
Kerestore 2.0	1.00
Crotein WKP	0.50
Parfum	0.50
Preservative	0.10
Citric Acid	To pH 5.0-6.0

Iberchem ingredients	
“Parfum”	
Top Notes comprising 4 ingredients	
Middle Notes comprising 4 ingredients	
Base Notes comprising 4 ingredients	

Well placed to adapt to consumer demand for more sustainable raw materials

- Croda ingredients**
- Boosts and stabilises foam
 - Provides viscosity
 - Solubiliser for fragrances and oil
 - Agent for hair glossing
 - Active for targeted hair repair
 - Protein-based moisturising active


Significant cross selling opportunities



Region	Croda	Iberchem
Europe	37%	17%
N America	27%	-
Latam	10%	8%
Asia	22%	36%
Middle East	2%	17%
Africa	2%	22%

Driving our focus on Consumer Care

- Group's Core Business will comprise 3 sectors:
 - Consumer Care
 - Life Sciences
 - Performance Technologies
- New Consumer Care sector from 2021
- Comparative 2020 numbers to be included at Croda's Full Year 2020 results, February 2021



Compelling strategic rationale

Compelling strategic rationale	
1.	Excellent financial track record
2.	Access to high growth adjacency with significant emerging markets exposure
3.	Creates a one stop shop for Consumer Care customers
4.	Long-standing, agile and responsive customer-centric model
5.	Dynamic, customer-driven R&D focus

CRODA

iberchem
FRAGRANCES OF NATURE

CRODA